Clinical Trials | December 29, 2025
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Subscribe To Our Newsletter & Stay Updated
